Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.47 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 2/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7231347 | 0.87 | MAPK1 (0.67) | MAPK14MAPK1PKMMEN1KMT2A | |
| SCHEMBL20604197 | 0.84 | MAPK14 (0.57) | MAPK14MAPK1SMN1; SMN2NOTUMNPC1 | |
| SCHEMBL6052554 | 0.84 | NOTUM (0.55) | MAPK14MAPK1MEN1KMT2ANOTUM | |
| SCHEMBL20604105 | 0.84 | WNT3A (0.58) | MAPK14MAPK1PKMSMN1; SMN2NPC1 | |
| SCHEMBL20604094 | 0.84 | NR4A3 (0.56) | MAPK14MAPK1PKMSMN1; SMN2NPC1 | |
| SCHEMBL19997263 | 0.83 | MAPK14 (0.52) | MAPK14MAPK1PKMMEN1KMT2A | |
| SCHEMBL17321485 | 0.83 | PKM (0.53) | MAPK14MAPK1PKMMEN1KMT2A | |
| SCHEMBL20604158 | 0.82 | MAPK1 (0.51) | MAPK14MAPK1PKMNPC1RAB9A | |
| SCHEMBL6320610 | 0.82 | MAPK14 (0.61) | MAPK14MAPK1PKMMEN1KMT2A | |
| SCHEMBL6312297 | 0.82 | ALDH1A1 (0.55) | MAPK14MAPK1SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| EP-3423452-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2019-01-09 | — | — | EP | disclosed |
| WO-2008130322-A1 | NOVEL 5-HETEROCYCLYL-CHROMANE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MAPK14 262/4885MAPK1 141/4885PKM 3403/4885 |
| US-20200299261-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | MAPK14 262/4885MAPK1 141/4885PKM 3403/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MAPK14 262/4885MAPK1 141/4885PKM 3403/4885 |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | WNT1, CTNNB1, WNT3A | MAPK14 262/4885MAPK1 141/4885PKM 3403/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MAPK14 262/4885MAPK1 141/4885PKM 3403/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | MAPK14 116/4885MAPK1 475/4885PKM 4549/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | MAPK14 262/4885MAPK1 141/4885PKM 3403/4885 |
| US-10723715-B2 | — | CTNNB1, WNT1, CTNNBL1 | MAPK14 1125/4885MAPK1 1136/4885PKM 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.